PYFA Records Sales Increase in Q1-2025 and Intensifies Global Expansion

Jakarta, 23 Juli 2025 — PT Pyridam Farma Tbk (Stock Code: PYFA), a public company engaged in the pharmaceutical sector, concluded the first quarter of 2025 with a solid performance and demonstrated a strong commitment to integrated expansion in the regional and global pharmaceutical sectors. Based on the consolidated financial report as of March 31, 2025, PYFA successfully recorded a net income of Rp685.46 billion, which is an approximately 325% growth compared to the same period in the previous year. The company’s EBITDA was Rp56.07 billion, and its gross profit was Rp180.24 billion, an increase from Rp59.07 billion in Q1-2024.

The Chief Financial Officer, Sinta Lestari Ningsih, stated that this achievement reflects the strong foundation in executing the company’s long-term strategy.

“The first quarter performance proves the resilience and effectiveness of our business model, as well as PYFA’s readiness to enter the next growth phase through production facility expansion and R&D innovation,” she said.

Furthermore, quoting from PYFA’s Public Expose on June 18, 2025, PYFA continues to strengthen its position as a regional player through an integrated expansion strategy that includes developing domestic production capacity, consolidating overseas facilities, and enhancing product research and innovation capabilities. One of the main initiatives is the development of the production facility of PYFA’s subsidiary, Ethica Industri Farmasi, in Cikarang, West Java, which is targeted to be fully operational by 2027. This project includes the construction of three new production lines and a relayout of the existing area, which is projected to provide an additional sales potential estimated at Rp300 billion per year. The Ethica facility is currently known as a high-standard sterile injection production center that is an important part of the regional supply chain.

At the international level, PYFA, through its subsidiary Probiotec Pty Ltd in Australia, is in the process of consolidating four facilities into one modern integrated location spanning 36,000 m2 in Kemps Creek, West Sydney. This facility will become one of the largest pharmaceutical and FMCG product packaging facilities in Australia, equipped with a high automation system, GMP/TGA certification, and will utilize renewable energy sources for up to 30% of its total operational needs. 

The President Director of PYFA, Lee Yan Gwan, stated, “As we presented at the 2025 public expose, this integrated expansion step is a crucial foundation for our global growth strategy. We are strengthening the value chain from upstream to downstream, from R&D to production and distribution. This is, of course, to make PYFA a reliable and competitive industry partner at both the regional and international levels,” he said.

As part of its innovation strengthening, PYFA is also collaborating with the global company XtalPi, which is known for utilizing artificial intelligence technology, allowing for faster drug trials with higher data accuracy. This collaboration strengthens PYFA’s internal R&D capabilities to be more responsive to global market dynamics and more efficient in terms of costs and development time. 

With the strategies and initiatives planned by PYFA, including the expansion of production facilities, cross-country operational integration, strategic research partnerships, and the development of new products, PYFA aims for sustainable sales and EBITDA growth. 

As a public company listed on the Indonesia Stock Exchange, PYFA is committed to implementing good corporate governance (GCG) principles and ensuring regular information disclosure in accordance with applicable regulations and routinely reported to the Exchange authorities.